drugset / Trial / NCT00979134

Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

NCT00979134

Phase 1 Terminated 95 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

This study is primarily designed to assess the safety and tolerability of AZD4547 at increasing doses in patients with advanced solid malignancies and for whom no standard medication options are available. It also assesses the blood levels and action of AZD4547 in the body over a period of time.

Timeline

Start
2009-10-21
Primary completion
2014-02-12
Completion
2015-03-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Fexagratinib Small molecule 80 mg Oral